Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1215 entries
Sorted by: Best Match Show Resources per page
Waist circumference and insulin resistance: a community based cross sectional study on reproductive aged Iranian women.

Diabetology & metabolic syndrome

Zadeh-Vakili A, Tehrani FR, Hosseinpanah F.
PMID: 21831271
Diabetol Metab Syndr. 2011 Aug 10;3:18. doi: 10.1186/1758-5996-3-18.

BACKGROUND: Although the positive relationship between insulin resistance (IR) and central obesity is well known, the direct relationship between waist circumference and IR is not clear yet and there is no consensus regarding the cut off value for waist...

Cite
Zadeh-Vakili A, Tehrani FR, Hosseinpanah F. Waist circumference and insulin resistance: a community based cross sectional study on reproductive aged Iranian women. Diabetol Metab Syndr. 2011;3:18doi: 10.1186/1758-5996-3-18.
Zadeh-Vakili, A., Tehrani, F. R., & Hosseinpanah, F. (2011). Waist circumference and insulin resistance: a community based cross sectional study on reproductive aged Iranian women. Diabetology & metabolic syndrome, 318. https://doi.org/10.1186/1758-5996-3-18
Zadeh-Vakili, Azita, et al. "Waist circumference and insulin resistance: a community based cross sectional study on reproductive aged Iranian women." Diabetology & metabolic syndrome vol. 3 (2011): 18. doi: https://doi.org/10.1186/1758-5996-3-18
Zadeh-Vakili A, Tehrani FR, Hosseinpanah F. Waist circumference and insulin resistance: a community based cross sectional study on reproductive aged Iranian women. Diabetol Metab Syndr. 2011 Aug 10;3:18. doi: 10.1186/1758-5996-3-18. PMID: 21831271; PMCID: PMC3170572.
Copy Download .nbib Format: NLM
Precocious markers of cardiovascular risk and vascular damage in apparently healthy women with previous gestational diabetes.

Diabetology & metabolic syndrome

Zajdenverg L, Rodacki M, Faria JP, Pires ML, Oliveira JE, Halfoun VL.
PMID: 24955136
Diabetol Metab Syndr. 2014 May 26;6:63. doi: 10.1186/1758-5996-6-63. eCollection 2014.

UNLABELLED: Previous gestational diabetes mellitus (pGDM) indicates future risk for type 2 diabetes (T2DM). Insulin resistance (IR) may precede T2DM in many years and is associated with an increased risk for cardiovascular diseases.AIM: This study aims to identify endothelial...

Cite
Zajdenverg L, Rodacki M, Faria JP, et al. Precocious markers of cardiovascular risk and vascular damage in apparently healthy women with previous gestational diabetes. Diabetol Metab Syndr. 2014;6:63doi: 10.1186/1758-5996-6-63.
Zajdenverg, L., Rodacki, M., Faria, J. P., Pires, M. L., Oliveira, J. E., & Halfoun, V. L. (2014). Precocious markers of cardiovascular risk and vascular damage in apparently healthy women with previous gestational diabetes. Diabetology & metabolic syndrome, 663. https://doi.org/10.1186/1758-5996-6-63
Zajdenverg, Lenita, et al. "Precocious markers of cardiovascular risk and vascular damage in apparently healthy women with previous gestational diabetes." Diabetology & metabolic syndrome vol. 6 (2014): 63. doi: https://doi.org/10.1186/1758-5996-6-63
Zajdenverg L, Rodacki M, Faria JP, Pires ML, Oliveira JE, Halfoun VL. Precocious markers of cardiovascular risk and vascular damage in apparently healthy women with previous gestational diabetes. Diabetol Metab Syndr. 2014 May 26;6:63. doi: 10.1186/1758-5996-6-63. eCollection 2014. PMID: 24955136; PMCID: PMC4064263.
Copy Download .nbib Format: NLM
The impact of abnormal glucose regulation on arterial stiffness at 3 and 15 months after kidney transplantation.

Diabetology & metabolic syndrome

Viecelli A, Nguyen HT, Yong K, Chan D, Dogra G, Wong G, Lim WH.
PMID: 24716893
Diabetol Metab Syndr. 2014 Apr 10;6(1):52. doi: 10.1186/1758-5996-6-52.

BACKGROUND: Post-transplant diabetes mellitus (PTDM) has been associated with an increased risk of cardiovascular disease (CVD) mortality following kidney transplantation, but the association between pre-diabetes (i.e. impaired fasting glucose and impaired glucose tolerance) and CVD mortality remains unclear. The...

Cite
Viecelli A, Nguyen HT, Yong K, et al. The impact of abnormal glucose regulation on arterial stiffness at 3 and 15 months after kidney transplantation. Diabetol Metab Syndr. 2014;6(1):52doi: 10.1186/1758-5996-6-52.
Viecelli, A., Nguyen, H. T., Yong, K., Chan, D., Dogra, G., Wong, G., & Lim, W. H. (2014). The impact of abnormal glucose regulation on arterial stiffness at 3 and 15 months after kidney transplantation. Diabetology & metabolic syndrome, 6(1), 52. https://doi.org/10.1186/1758-5996-6-52
Viecelli, Andrea, et al. "The impact of abnormal glucose regulation on arterial stiffness at 3 and 15 months after kidney transplantation." Diabetology & metabolic syndrome vol. 6,1 (2014): 52. doi: https://doi.org/10.1186/1758-5996-6-52
Viecelli A, Nguyen HT, Yong K, Chan D, Dogra G, Wong G, Lim WH. The impact of abnormal glucose regulation on arterial stiffness at 3 and 15 months after kidney transplantation. Diabetol Metab Syndr. 2014 Apr 10;6(1):52. doi: 10.1186/1758-5996-6-52. PMID: 24716893; PMCID: PMC3984428.
Copy Download .nbib Format: NLM
Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus.

Diabetology & metabolic syndrome

Duvnjak L, Blaslov K.
PMID: 27006706
Diabetol Metab Syndr. 2016 Mar 22;8:26. doi: 10.1186/s13098-016-0144-6. eCollection 2016.

BACKGROUND: This uncontrolled open label study evaluated the effect of dipeptidyl peptidase-4 inhibitors (DPP-4i): sitagliptin and vildagliptin on augmentation index standardized for 75 beats per minute (cAiX@75), blood pressure (BP), lipid profile and high-sensitivity C-reactive protein (hsCRP) in patients...

Cite
Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2016;8:26doi: 10.1186/s13098-016-0144-6.
Duvnjak, L., & Blaslov, K. (2016). Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetology & metabolic syndrome, 826. https://doi.org/10.1186/s13098-016-0144-6
Duvnjak, Lea, and Blaslov, Kristina. "Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus." Diabetology & metabolic syndrome vol. 8 (2016): 26. doi: https://doi.org/10.1186/s13098-016-0144-6
Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2016 Mar 22;8:26. doi: 10.1186/s13098-016-0144-6. eCollection 2016. PMID: 27006706; PMCID: PMC4802883.
Copy Download .nbib Format: NLM
Prevalence of metabolic syndrome in non-diabetic, pregnant Angolan women according to four diagnostic criteria and its effects on adverse perinatal outcomes.

Diabetology & metabolic syndrome

Dos Prazeres Tavares H, Dos Santos DC, Abbade JF, Negrato CA, de Campos PA, Calderon IM, Rudge MV.
PMID: 27006707
Diabetol Metab Syndr. 2016 Mar 22;8:27. doi: 10.1186/s13098-016-0139-3. eCollection 2016.

BACKGROUND: Metabolic syndrome (MetS) is a cluster of risk factors for type 2 diabetes (Type2 DM) and cardiovascular diseases (CVD), and its prevalence varies based on region, population, and sex. Newborns of women with MetS have a greater risk...

Cite
Dos Prazeres Tavares H, Dos Santos DC, Abbade JF, et al. Prevalence of metabolic syndrome in non-diabetic, pregnant Angolan women according to four diagnostic criteria and its effects on adverse perinatal outcomes. Diabetol Metab Syndr. 2016;8:27doi: 10.1186/s13098-016-0139-3.
Dos Prazeres Tavares, H., Dos Santos, D. C., Abbade, J. F., Negrato, C. A., de Campos, P. A., Calderon, I. M., & Rudge, M. V. (2016). Prevalence of metabolic syndrome in non-diabetic, pregnant Angolan women according to four diagnostic criteria and its effects on adverse perinatal outcomes. Diabetology & metabolic syndrome, 827. https://doi.org/10.1186/s13098-016-0139-3
Dos Prazeres Tavares, Hamilton, et al. "Prevalence of metabolic syndrome in non-diabetic, pregnant Angolan women according to four diagnostic criteria and its effects on adverse perinatal outcomes." Diabetology & metabolic syndrome vol. 8 (2016): 27. doi: https://doi.org/10.1186/s13098-016-0139-3
Dos Prazeres Tavares H, Dos Santos DC, Abbade JF, Negrato CA, de Campos PA, Calderon IM, Rudge MV. Prevalence of metabolic syndrome in non-diabetic, pregnant Angolan women according to four diagnostic criteria and its effects on adverse perinatal outcomes. Diabetol Metab Syndr. 2016 Mar 22;8:27. doi: 10.1186/s13098-016-0139-3. eCollection 2016. PMID: 27006707; PMCID: PMC4802648.
Copy Download .nbib Format: NLM
Mesenchymal stem cell therapy in type 2 diabetes mellitus.

Diabetology & metabolic syndrome

Zang L, Hao H, Liu J, Li Y, Han W, Mu Y.
PMID: 28515792
Diabetol Metab Syndr. 2017 May 15;9:36. doi: 10.1186/s13098-017-0233-1. eCollection 2017.

Type 2 diabetes mellitus (T2DM), which is characterized by the combination of relative insulin deficiency and insulin resistance, cannot be reversed with existing therapeutic strategies. Transplantation of insulin-producing cells (IPCs) was once thought to be the most promising strategy...

Cite
Zang L, Hao H, Liu J, et al. Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:36doi: 10.1186/s13098-017-0233-1.
Zang, L., Hao, H., Liu, J., Li, Y., Han, W., & Mu, Y. (2017). Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetology & metabolic syndrome, 936. https://doi.org/10.1186/s13098-017-0233-1
Zang, Li, et al. "Mesenchymal stem cell therapy in type 2 diabetes mellitus." Diabetology & metabolic syndrome vol. 9 (2017): 36. doi: https://doi.org/10.1186/s13098-017-0233-1
Zang L, Hao H, Liu J, Li Y, Han W, Mu Y. Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetol Metab Syndr. 2017 May 15;9:36. doi: 10.1186/s13098-017-0233-1. eCollection 2017. PMID: 28515792; PMCID: PMC5433043.
Copy Download .nbib Format: NLM
Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2.

Diabetology & metabolic syndrome

Valerio CM, de Almeida JS, Moreira RO, Aguiar LBS, Siciliano PO, Carvalho DP, Godoy-Matos AF.
PMID: 28450900
Diabetol Metab Syndr. 2017 Apr 24;9:26. doi: 10.1186/s13098-017-0226-0. eCollection 2017.

BACKGROUND: Dipeptidyl peptidase-4 (DDP4) is an enzyme responsible for glucagon-like peptide-1 inactivation and plays an important role in glucose metabolism.OBJECTIVE: The aim of this study was to evaluate DPP4 levels in patients with familial partial lipodystrophy type 2 (FPLD2)...

Cite
Valerio CM, de Almeida JS, Moreira RO, et al. Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. Diabetol Metab Syndr. 2017;9:26doi: 10.1186/s13098-017-0226-0.
Valerio, C. M., de Almeida, J. S., Moreira, R. O., Aguiar, L. B. S., Siciliano, P. O., Carvalho, D. P., & Godoy-Matos, A. F. (2017). Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. Diabetology & metabolic syndrome, 926. https://doi.org/10.1186/s13098-017-0226-0
Valerio, Cynthia Melissa, et al. "Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2." Diabetology & metabolic syndrome vol. 9 (2017): 26. doi: https://doi.org/10.1186/s13098-017-0226-0
Valerio CM, de Almeida JS, Moreira RO, Aguiar LBS, Siciliano PO, Carvalho DP, Godoy-Matos AF. Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. Diabetol Metab Syndr. 2017 Apr 24;9:26. doi: 10.1186/s13098-017-0226-0. eCollection 2017. PMID: 28450900; PMCID: PMC5404683.
Copy Download .nbib Format: NLM
Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.

Diabetology & metabolic syndrome

Seino H, Onishi Y, Naito Y, Komatsu M.
PMID: 27252787
Diabetol Metab Syndr. 2016 Jun 01;8:36. doi: 10.1186/s13098-016-0151-7. eCollection 2016.

BACKGROUND: The GetGoal-L-Asia and -S trials were multi-center trials conducted in 4 and 16 countries, respectively including Japan that evaluated the efficacy and safety of lixisenatide add-on treatment vs. placebo among patients with type 2 diabetes. The aims of...

Cite
Seino H, Onishi Y, Naito Y, et al. Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis. Diabetol Metab Syndr. 2016;8:36doi: 10.1186/s13098-016-0151-7.
Seino, H., Onishi, Y., Naito, Y., & Komatsu, M. (2016). Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis. Diabetology & metabolic syndrome, 836. https://doi.org/10.1186/s13098-016-0151-7
Seino, Hiroaki, et al. "Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis." Diabetology & metabolic syndrome vol. 8 (2016): 36. doi: https://doi.org/10.1186/s13098-016-0151-7
Seino H, Onishi Y, Naito Y, Komatsu M. Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis. Diabetol Metab Syndr. 2016 Jun 01;8:36. doi: 10.1186/s13098-016-0151-7. eCollection 2016. PMID: 27252787; PMCID: PMC4888474.
Copy Download .nbib Format: NLM
Eicosapentaenoic acid/arachidonic acid ratio and smoking status in elderly patients with type 2 diabetes mellitus.

Diabetology & metabolic syndrome

Okada K, Kotani K, Yagyu H, Ishibashi S.
PMID: 25143787
Diabetol Metab Syndr. 2014 Aug 13;6(1):85. doi: 10.1186/1758-5996-6-85. eCollection 2014.

BACKGROUND: A low ratio of eicosapentaenoic acid (EPA)/arachidonic acid (AA) is considered a risk factor for cardiovascular disease. Smoking is also a risk factor for cardiovascular disease even in an elderly population. This study investigated the relationship between EPA/AA...

Cite
Okada K, Kotani K, Yagyu H, et al. Eicosapentaenoic acid/arachidonic acid ratio and smoking status in elderly patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2014;6(1):85doi: 10.1186/1758-5996-6-85.
Okada, K., Kotani, K., Yagyu, H., & Ishibashi, S. (2014). Eicosapentaenoic acid/arachidonic acid ratio and smoking status in elderly patients with type 2 diabetes mellitus. Diabetology & metabolic syndrome, 6(1), 85. https://doi.org/10.1186/1758-5996-6-85
Okada, Kenta, et al. "Eicosapentaenoic acid/arachidonic acid ratio and smoking status in elderly patients with type 2 diabetes mellitus." Diabetology & metabolic syndrome vol. 6,1 (2014): 85. doi: https://doi.org/10.1186/1758-5996-6-85
Okada K, Kotani K, Yagyu H, Ishibashi S. Eicosapentaenoic acid/arachidonic acid ratio and smoking status in elderly patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2014 Aug 13;6(1):85. doi: 10.1186/1758-5996-6-85. eCollection 2014. PMID: 25143787; PMCID: PMC4138366.
Copy Download .nbib Format: NLM
Validity of a continuous metabolic syndrome score as an index for modeling metabolic syndrome in children and adolescents: the CASPIAN-V study.

Diabetology & metabolic syndrome

Heshmat R, Heidari M, Ejtahed HS, Motlagh ME, Mahdavi-Gorab A, Ziaodini H, Taheri M, Shafiee G, Beshtar S, Qorbani M, Kelishadi R.
PMID: 29151898
Diabetol Metab Syndr. 2017 Nov 09;9:89. doi: 10.1186/s13098-017-0291-4. eCollection 2017.

BACKGROUND: The purpose of the present study was to assess the validity of continuous metabolic syndrome score (cMetS) for predicting metabolic syndrome (MetS) and to determine the cutoff values in a representative sample of Iranian children and adolescents.METHODS: This...

Cite
Heshmat R, Heidari M, Ejtahed HS, et al. Validity of a continuous metabolic syndrome score as an index for modeling metabolic syndrome in children and adolescents: the CASPIAN-V study. Diabetol Metab Syndr. 2017;9:89doi: 10.1186/s13098-017-0291-4.
Heshmat, R., Heidari, M., Ejtahed, H. S., Motlagh, M. E., Mahdavi-Gorab, A., Ziaodini, H., Taheri, M., Shafiee, G., Beshtar, S., Qorbani, M., & Kelishadi, R. (2017). Validity of a continuous metabolic syndrome score as an index for modeling metabolic syndrome in children and adolescents: the CASPIAN-V study. Diabetology & metabolic syndrome, 989. https://doi.org/10.1186/s13098-017-0291-4
Heshmat, Ramin, et al. "Validity of a continuous metabolic syndrome score as an index for modeling metabolic syndrome in children and adolescents: the CASPIAN-V study." Diabetology & metabolic syndrome vol. 9 (2017): 89. doi: https://doi.org/10.1186/s13098-017-0291-4
Heshmat R, Heidari M, Ejtahed HS, Motlagh ME, Mahdavi-Gorab A, Ziaodini H, Taheri M, Shafiee G, Beshtar S, Qorbani M, Kelishadi R. Validity of a continuous metabolic syndrome score as an index for modeling metabolic syndrome in children and adolescents: the CASPIAN-V study. Diabetol Metab Syndr. 2017 Nov 09;9:89. doi: 10.1186/s13098-017-0291-4. eCollection 2017. PMID: 29151898; PMCID: PMC5679142.
Copy Download .nbib Format: NLM
Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats.

Diabetology & metabolic syndrome

Zhang L, Song X, Zhou L, Liang G, Xu H, Wang F, Huang F, Jiang G.
PMID: 27956941
Diabetol Metab Syndr. 2016 Nov 29;8:78. doi: 10.1186/s13098-016-0194-9. eCollection 2016.

BACKGROUND: Our recent findings support the idea that 3-deoxyglucosone (3DG), a dietary composition, has been suggested as an independent factor for the development of prediabetes. Secretion of glucagon-like peptide-1 (GLP-1) has been suggested to be impaired in T2DM and...

Cite
Zhang L, Song X, Zhou L, et al. Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats. Diabetol Metab Syndr. 2016;8:78doi: 10.1186/s13098-016-0194-9.
Zhang, L., Song, X., Zhou, L., Liang, G., Xu, H., Wang, F., Huang, F., & Jiang, G. (2016). Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats. Diabetology & metabolic syndrome, 878. https://doi.org/10.1186/s13098-016-0194-9
Zhang, Lurong, et al. "Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats." Diabetology & metabolic syndrome vol. 8 (2016): 78. doi: https://doi.org/10.1186/s13098-016-0194-9
Zhang L, Song X, Zhou L, Liang G, Xu H, Wang F, Huang F, Jiang G. Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats. Diabetol Metab Syndr. 2016 Nov 29;8:78. doi: 10.1186/s13098-016-0194-9. eCollection 2016. PMID: 27956941; PMCID: PMC5129672.
Copy Download .nbib Format: NLM
Obesity and hypertensive heart disease: focus on body composition and sex differences.

Diabetology & metabolic syndrome

de Simone G, Mancusi C, Izzo R, Losi MA, Aldo Ferrara L.
PMID: 27956942
Diabetol Metab Syndr. 2016 Nov 30;8:79. doi: 10.1186/s13098-016-0193-x. eCollection 2016.

There is evidence that hypertension is frequently associated with overweight/obesity even in kids and adolescents. Either conditions influence development of left ventricular (LV) hypertrophy (LVH), through different biological and hemodynamic mechanisms: obesity is conventionally thought to elicit a coherent...

Cite
de Simone G, Mancusi C, Izzo R, et al. Obesity and hypertensive heart disease: focus on body composition and sex differences. Diabetol Metab Syndr. 2016;8:79doi: 10.1186/s13098-016-0193-x.
de Simone, G., Mancusi, C., Izzo, R., Losi, M. A., & Aldo Ferrara, L. (2016). Obesity and hypertensive heart disease: focus on body composition and sex differences. Diabetology & metabolic syndrome, 879. https://doi.org/10.1186/s13098-016-0193-x
de Simone, Giovanni, et al. "Obesity and hypertensive heart disease: focus on body composition and sex differences." Diabetology & metabolic syndrome vol. 8 (2016): 79. doi: https://doi.org/10.1186/s13098-016-0193-x
de Simone G, Mancusi C, Izzo R, Losi MA, Aldo Ferrara L. Obesity and hypertensive heart disease: focus on body composition and sex differences. Diabetol Metab Syndr. 2016 Nov 30;8:79. doi: 10.1186/s13098-016-0193-x. eCollection 2016. PMID: 27956942; PMCID: PMC5129668.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1215 entries